Initial Statement of Beneficial Ownership (3)
November 09 2021 - 3:51PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Johnson Shane Aaron |
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/2/2021
|
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [INM]
|
(Last)
(First)
(Middle)
C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST. |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) SVP & GM of BayMedica LLC / |
(Street)
VANCOUVER, A1 V6C1B4
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 4574 | D | |
Common Stock | 278428 | I | By Shane A. Johnson TTEE of the Shane A. Johnson Trust DTD April 18, 1997, as amended |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Buy) | (1) | 10/17/2026 | Common shares | 60000 | $1.40 | D | |
Employee Stock Option (Right to Buy) | (2) | 10/17/2026 | Common shares | 35000 | $1.40 | D | |
Explanation of Responses: |
(1) | The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. |
(2) | Complete vesting shall occur on the one year anniversary of the grant date (October 18, 2022). |
Remarks: Exhibit 24 - Power of Attorney |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Johnson Shane Aaron C/O INMED PHARMACEUTICALS INC. 310-815 WEST HASTINGS ST. VANCOUVER, A1 V6C1B4 |
|
| SVP & GM of BayMedica LLC |
|
Signatures
|
/s/ Bruce S. Colwill, by power-of-attorney | | 11/9/2021 |
**Signature of Reporting Person | Date |
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024